Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-23-058861

Options or other derivatives

  • Chief R&D Officer acquired 250,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-12-13 Grant or award : show line 1 in the form Stock Option +250,000 250,000 D
Loading xslF345X05/doc4.xml…